Search

Your search keyword '"Miglietta, Loredana"' showing total 12 results
Start Over Author "Miglietta, Loredana" Search Limiters Full Text
12 results on '"Miglietta, Loredana"'

5. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, primary, Anserini, Paola, additional, Fontana, Valeria, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Abate, Annalisa, additional, Levaggi, Alessia, additional, Miglietta, Loredana, additional, Bighin, Claudia, additional, Giraudi, Sara, additional, D’Alonzo, Alessia, additional, Blondeaux, Eva, additional, Buffi, Davide, additional, Campone, Francesco, additional, Merlo, Domenico F., additional, and Del Mastro, Lucia, additional

Published
2017
Full Text
View/download PDF

6. Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases.

Author

Buonomo, Barbara, Brunello, Antonella, Noli, Stefania, Miglietta, Loredana, Del Mastro, Lucia, Lambertini, Matteo, and Peccatori, Fedro Alessandro

Subjects
BREAST tumors, COMBINED modality therapy, CONTRACEPTION, COUNSELING, HEALTH care teams, TAMOXIFEN, SYSTEMATIC reviews, PERIMENOPAUSE, MATERNAL exposure, PREGNANCY
Abstract

Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. According to guidelines, the use of nonhormonal barrier contraception is recommended during tamoxifen treatment and up to 3 months after its interruption prior to attempting conception. Nevertheless, when conception occurs inadvertently during tamoxifen treatment, the effects on the fetus and on the course of pregnancy are still not completely known. Here, we report 3 cases of young women who accidentally became pregnant while taking tamoxifen and perform a systematic review of the literature to provide more elements for better and clear multidisciplinary counselling of women facing this challenging situation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

7. The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, Bighin, Claudia, Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, and Bighin, Claudia

Abstract

Background: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. Methods: The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously exposed to anticancer therapies. The primary objective is to obtain and centralize data about patients' preferences and choices towards the available fertility preserving procedures. The success and safety of these strategies and the hormonal changes during chemotherapy and study follow-up are secondary objectives. The PREFER-PREGNANCY study is enrolling survivors achieving a pregnancy after prior history of breast cancer and patients diagnosed with pregnancy-associated breast cancer (PABC). The primary objectives are to obtain and centralize data about the management and clinical outcomes of these women. Patients' survival outcomes, and the fetal, obstetrical and paediatric care of their children are secondary objectives. For both studies, the initial planned recruitment period is 5 years and patients will remain in active follow-up for up to 15 years. The PREFER-FERTILITY study was first activated in November 2012, and the PREFER-PREGNANCY study i, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

8. Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study

Author

Bighin, Claudia, primary, Dozin, Beatrice, additional, Poggio, Francesca, additional, Ceppi, Marcello, additional, Bruzzi, Paolo, additional, D’Alonzo, Alessia, additional, Levaggi, Alessia, additional, Giraudi, Sara, additional, Lambertini, Matteo, additional, Miglietta, Loredana, additional, Vaglica, Marina, additional, Fontana, Vincenzo, additional, Iacono, Giuseppina, additional, Pronzato, Paolo, additional, and Mastro, Lucia Del, additional

Published
2017
Full Text
View/download PDF

9. PO54 ACTIVITY AND DURATION OF CHEMOTHERAPY IN DIFFERENT BIOLOGIC SUBTYPES (BS) IN METASTATIC BREAST CANCER (MBC) PATIENTS

Author

Lambertini, Matteo, primary, Bighin, Claudia, additional, Del Mastro, Lucia, additional, Dozin, Beatrice, additional, Levaggi, Alessia, additional, Giraudi, Sara, additional, D'Alonzo, Alessia, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Vecchio, Stefania, additional, Miglietta, Loredana, additional, and Pronzato, Paolo, additional

Published
2013
Full Text
View/download PDF

12. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.

Author

Miglietta L, Vanella P, Canobbio L, Parodi MA, Guglielmini P, and Boccardo F

Subjects
Breast Neoplasms metabolism, Breast Neoplasms pathology, Female, Humans, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Cell Proliferation, Ki-67 Antigen metabolism, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
Abstract

Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC)., Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression., Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate., Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results